Wangwen Gu
Impact in
- Biomaterials top 0.5%
- Nanoparticle-Based Drug Delivery
- Pharmaceutical Science top 1%
- Advanced Drug Delivery Systems
Papers in
-
- RNA Interference and Gene Delivery 19
- Advanced biosensing and bioanalysis techniques 16
- Biomaterials 17
- Nanoparticle-Based Drug Delivery 17
- Co-authors
- Yaping Li (37 shared papers)Zhiwen Zhang (27 shared papers)Haijun Yu (16 shared papers)Qi Yin (14 shared papers)Lingli Chen (18 shared papers)Lingli Chen (11 shared papers)Yu Gao (12 shared papers)Qingshuo Meng (8 shared papers)
- Journals
- Biomaterials (8 papers)Advanced Functional Materials (6 papers)Biomacromolecules (5 papers)International Journal of Pharmaceutics (5 papers)Molecular Pharmaceutics (3 papers)
- Partner nations
- ChinaUnited States
In The Last Decade
Wangwen Gu
38 papers receiving 2.9k citations
Wangwen Gu's Hit Papers
Peers
Comparison fields: 5 of 102
- Biomaterials 1.4k
- Pharmaceutical Science 243
- Biomedical Engineering 1.4k
- Molecular Biology 1.3k
- Molecular Medicine 83
Countries citing papers authored by Wangwen Gu
This map shows the geographic impact of Wangwen Gu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wangwen Gu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wangwen Gu more than expected).
Fields of papers citing papers by Wangwen Gu
This network shows the impact of papers produced by Wangwen Gu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wangwen Gu. The network helps show where Wangwen Gu may publish in the future.
Co-authors
The 25 scholars most cited alongside Wangwen Gu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 39 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Cancer‐Cell‐Biomimetic Nanoparticles for Targeted Therapy of Homotypic Tumors Hit paper breakdown → | 2016 | 556 |
| 2 | 2016 | 321 | |
| 3 | 2008 | 246 | |
| 4 | 2015 | 128 | |
| 5 | 2008 | 119 | |
| 6 | 2004 | 116 | |
| 7 | 2015 | 108 | |
| 8 | 2014 | 108 | |
| 9 | 2016 | 98 | |
| 10 | 2012 | 88 | |
| 11 | 2015 | 88 | |
| 12 | 2016 | 87 | |
| 13 | 2015 | 72 | |
| 14 | 2008 | 67 | |
| 15 | 2009 | 62 | |
| 16 | 2013 | 58 | |
| 17 | 2013 | 57 | |
| 18 | 2006 | 57 | |
| 19 | 2016 | 50 | |
| 20 | 2008 | 49 |
About Wangwen Gu
Wangwen Gu is a scholar working on Molecular Biology, Biomaterials, Biomedical Engineering, Oncology and Genetics, having authored 39 papers that have together received 2.9k indexed citations. Recurring topics across this work include RNA Interference and Gene Delivery (19 papers), Nanoparticle-Based Drug Delivery (17 papers), Advanced biosensing and bioanalysis techniques (16 papers), Nanoplatforms for cancer theranostics (12 papers), Virus-based gene therapy research (7 papers), Cancer Cells and Metastasis (5 papers), Drug Transport and Resistance Mechanisms (3 papers) and Vehicle emissions and performance (2 papers). The work is most often cited by research in Biomaterials (1.4k citations), Pharmaceutical Science (243 citations), Biomedical Engineering (1.4k citations), Molecular Biology (1.3k citations) and Molecular Medicine (83 citations). Wangwen Gu has collaborated with scholars based in China and United States. Frequent co-authors include Yaping Li, Zhiwen Zhang, Haijun Yu, Qi Yin, Lingli Chen, Lingli Chen, Yu Gao, Qingshuo Meng, Jinghan Su and Huiping Sun. Their work appears in journals such as Biomaterials, Advanced Functional Materials, Biomacromolecules, International Journal of Pharmaceutics and Molecular Pharmaceutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.